Merck & Co., Inc. MRK.MX · Stock Open Merck & Co., Inc. in new tab
Merck & Co., Inc. Analysis (MRK.MX)
Is Merck & Co., Inc. a good investment? Merck & Co., Inc. (MRK.MX) is currently trading at 2559.00 MXN.
In terms of valuation, the stock trades at a P/E ratio of 120.31. This high multiple suggests investors have priced in significant future growth expectations.
For income investors, Merck & Co., Inc. pays a dividend yield of 2.29%. With a payout ratio of 269%, the dividend appears to be under pressure.
Investor FAQ
Does Merck & Co., Inc. pay a dividend?
Yes, it pays an annual dividend of 59.40 MXN (2.29% yield).
What asset class is Merck & Co., Inc.?
Merck & Co., Inc. is classified as a Stock. You can compare it against 8 other assets in the "Related Symbols" list on this page.
Company Profile
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
| Year | Total Dividends |
|---|---|
| ▸2027 |
30.55 MXN
|
| June 14, 2027 (estimated) | 15.2751 |
| March 15, 2027 (estimated) | 15.2751 |
| ▸2026 |
58.64 MXN
|
| Dec. 14, 2026 (estimated) | 15.2260 |
| Sept. 15, 2026 | 14.5932 |
| June 15, 2026 | 14.4109 |
| March 17, 2026 | 14.4109 |
| ▸2025 |
55.61 MXN
|
| Dec. 15, 2025 | 14.4109 |
| Sept. 15, 2025 | 13.7327 |
| June 16, 2025 | 13.7327 |
| March 18, 2025 | 13.7327 |
| ▸2024 |
52.90 MXN
|
| Dec. 16, 2024 | 13.7327 |
| Sept. 17, 2024 | 13.0546 |
| June 17, 2024 | 13.0546 |
| March 14, 2024 | 13.0546 |
| ▸2023 |
50.18 MXN
|
| Dec. 14, 2023 | 13.0546 |
| Sept. 14, 2023 | 12.3764 |
| June 14, 2023 | 12.3764 |
| March 14, 2023 | 12.3764 |
| ▸2022 |
47.47 MXN
|
| Dec. 14, 2022 | 12.3764 |
| Sept. 14, 2022 | 11.6983 |
| June 14, 2022 | 11.6983 |
| March 14, 2022 | 11.6983 |
| ▸2021 |
44.76 MXN
|
| Dec. 14, 2021 | 11.6983 |
| Sept. 14, 2021 | 11.0201 |
| June 14, 2021 | 11.0201 |
| March 12, 2021 | 11.0201 |
| ▸2020 |
42.05 MXN
|
| Dec. 14, 2020 | 11.0201 |
| Sept. 14, 2020 | 10.3419 |
| June 12, 2020 | 10.3419 |
| March 13, 2020 | 10.3419 |
| ▸2019 |
38.32 MXN
|
| Dec. 13, 2019 | 10.3419 |
| Sept. 13, 2019 | 9.3247 |
| June 14, 2019 | 9.3247 |
| March 14, 2019 | 9.3247 |
| ▸2018 |
33.74 MXN
|
| Dec. 14, 2018 | 9.3247 |
| Sept. 14, 2018 | 8.1379 |
| June 14, 2018 | 8.1379 |
| March 14, 2018 | 8.1379 |
| ▸2017 |
32.04 MXN
|
| Dec. 14, 2017 | 8.1379 |
| Sept. 14, 2017 | 7.9684 |
| June 13, 2017 | 7.9684 |
| March 13, 2017 | 7.9684 |
| ▸2016 |
31.36 MXN
|
| Dec. 13, 2016 | 7.9684 |
| Sept. 13, 2016 | 7.7988 |
| June 13, 2016 | 7.7988 |
| March 11, 2016 | 7.7988 |
| ▸2015 |
30.69 MXN
|
| Dec. 11, 2015 | 7.7988 |
| Sept. 11, 2015 | 7.6293 |
| June 11, 2015 | 7.6293 |
| March 12, 2015 | 7.6293 |
| ▸2014 |
30.01 MXN
|
| Dec. 11, 2014 | 7.6293 |
| Sept. 11, 2014 | 7.4598 |
| June 12, 2014 | 7.4598 |
| March 13, 2014 | 7.4598 |
| ▸2013 |
29.33 MXN
|
| Dec. 11, 2013 | 7.4598 |
| Sept. 12, 2013 | 7.2902 |
| June 13, 2013 | 7.2902 |
| March 13, 2013 | 7.2902 |
| ▸2012 |
28.65 MXN
|
| Dec. 13, 2012 | 7.2902 |
| Sept. 12, 2012 | 7.1207 |
| June 13, 2012 | 7.1207 |
| March 13, 2012 | 7.1207 |
| ▸2011 |
26.45 MXN
|
| Dec. 13, 2011 | 7.1207 |
| Sept. 13, 2011 | 6.4425 |
| June 16, 2011 | 6.4425 |
| March 11, 2011 | 6.4425 |
| ▸2010 |
32.21 MXN
|
| Dec. 13, 2010 | 6.4425 |
| Sept. 13, 2010 | 6.4425 |
| June 16, 2010 | 6.4425 |
| June 11, 2010 | 6.4425 |
| March 11, 2010 | 6.4425 |
| ▸2009 |
25.77 MXN
|
| Dec. 11, 2009 | 6.4425 |
| Sept. 2, 2009 | 6.4425 |
| June 4, 2009 | 6.4425 |
| March 4, 2009 | 6.4425 |
| ▸2008 |
25.77 MXN
|
| Dec. 3, 2008 | 6.4425 |
| Sept. 3, 2008 | 6.4425 |
| June 4, 2008 | 6.4425 |
| March 5, 2008 | 6.4425 |
| ▸2007 |
25.77 MXN
|
| Dec. 5, 2007 | 6.4425 |
| Sept. 5, 2007 | 6.4425 |
| June 6, 2007 | 6.4425 |
| March 7, 2007 | 6.4425 |
| ▸2006 |
25.77 MXN
|
| Dec. 6, 2006 | 6.4425 |
| Aug. 30, 2006 | 6.4425 |
| May 31, 2006 | 6.4425 |
| March 8, 2006 | 6.4425 |
| ▸2005 |
25.77 MXN
|
| Nov. 30, 2005 | 6.4425 |
| Aug. 31, 2005 | 6.4425 |
| June 1, 2005 | 6.4425 |
| March 2, 2005 | 6.4425 |
| ▸2004 |
25.43 MXN
|
| Dec. 1, 2004 | 6.4425 |
| Sept. 1, 2004 | 6.4425 |
| June 2, 2004 | 6.2730 |
| March 3, 2004 | 6.2730 |
| ▸2003 |
18.65 MXN
|
| Dec. 3, 2003 | 6.2730 |
| Sept. 3, 2003 | 6.2730 |
| June 4, 2003 | 6.1034 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| Merck & Co., Inc. | Sep 15, 2026 | Paid | 14.59323 MXN |
| Merck & Co., Inc. | Jun 15, 2026 | Paid | 14.410901 MXN |
| Merck & Co., Inc. | Mar 17, 2026 | Paid | 14.410901 MXN |
| Merck & Co., Inc. | Dec 15, 2025 | Paid | 14.410901 MXN |
Community Discussion